IQV IQVIA HOLDINGS INC.
Services-Commercial Physical & Biological Research · NYSE · SEC CIK 1478242 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.8%
TTM net income YoY8.7%
TTM EPS YoY13.1%
Revenue 3-yr CAGR5.2%
Net income 3-yr CAGR7.7%
Margins
Gross margin33.1%
Operating margin12.8%
Net margin8.1%
FCF margin12.0%
EBITDA margin19.9%
Returns
ROE21.7%
ROA4.7%
ROIC (approx.)9.3%
Asset turnover0.58x
Leverage & solvency
Liabilities / assets77.7%
Debt / equity2.41x
Current ratio0.83x
Interest coverage2.83x
Cash quality & payout
Operating cash flow / net income1.96x
Accruals ratio-4.5%
Payout ratio—
Capex / revenue3.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $4.43B | $4.37B | $4.15B | $4.36B | $4.10B | $4.02B | $3.83B | $3.96B |
| Cost of revenue | $2.93B | $2.93B | $2.80B | $2.93B | $2.73B | $2.69B | $2.53B | $2.58B |
| Gross profit | $1.50B | $1.44B | $1.35B | $1.44B | $1.37B | $1.32B | $1.30B | $1.38B |
| SG&A expense | $569.00M | $574.00M | $502.00M | $468.00M | $514.00M | $509.00M | $508.00M | $453.00M |
| Operating income | $572.00M | $506.00M | $514.00M | $627.00M | $553.00M | $506.00M | $496.00M | $626.00M |
| Interest expense | $203.00M | $197.00M | $192.00M | $193.00M | $189.00M | $182.00M | $165.00M | $171.00M |
| Pretax income | $386.00M | $301.00M | $328.00M | $537.00M | $408.00M | $323.00M | $323.00M | $544.00M |
| Income tax | $76.00M | $60.00M | $59.00M | $59.00M | $76.00M | $56.00M | $61.00M | $112.00M |
| Net income | $350.00M | $256.00M | $274.00M | $514.00M | $331.00M | $266.00M | $249.00M | $437.00M |
| EBITDA | $893.00M | $798.00M | $802.00M | $944.00M | $839.00M | $782.00M | $761.00M | $929.00M |
| EPS (basic) | 2.13 | 1.54 | 1.63 | — | 1.94 | 1.55 | 1.42 | — |
| EPS (diluted) | 2.10 | 1.53 | 1.61 | — | 1.93 | 1.54 | 1.40 | — |
| Weighted avg. shares (diluted) | 167.00M | 167.30M | 169.80M | — | 171.70M | 173.20M | 177.40M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $2.25B | $1.91B | $1.95B | $1.98B | $1.81B | $2.04B | $1.74B | $1.70B |
| Short-term investments | $173.00M | $171.00M | $156.00M | $161.00M | $158.00M | $149.00M | $136.00M | $141.00M |
| Receivables | $3.29B | $3.35B | $3.35B | $3.40B | $3.27B | $3.34B | $3.27B | $3.20B |
| Current assets | $6.45B | $6.23B | $6.22B | $6.25B | $5.98B | $6.34B | $5.91B | $5.83B |
| PP&E, net | $534.00M | $547.00M | $516.00M | $533.00M | $525.00M | $536.00M | $533.00M | $535.00M |
| Goodwill | $16.90B | $16.60B | $16.54B | $16.62B | $15.95B | $15.61B | $15.03B | $14.71B |
| Intangibles | $4.74B | $4.75B | $4.80B | $4.96B | $4.71B | $4.60B | $4.50B | $4.50B |
| Total assets | $30.47B | $29.88B | $29.68B | $29.94B | $28.73B | $28.63B | $27.32B | $26.90B |
| Current liabilities | $7.78B | $8.81B | $8.33B | $8.34B | $8.51B | $7.57B | $7.18B | $6.96B |
| Short-term debt | $1.24B | $2.29B | $1.84B | $1.84B | $2.16B | $1.31B | $1.22B | $1.15B |
| Long-term debt | $14.82B | $13.71B | $13.99B | $13.88B | $12.79B | $14.18B | $13.11B | $12.84B |
| Total debt | $16.07B | $16.00B | $15.83B | $15.72B | $14.96B | $15.49B | $14.33B | $13.98B |
| Total liabilities | $23.68B | $23.58B | $23.33B | $23.31B | $22.44B | $22.85B | $21.34B | $20.83B |
| Shareholders' equity | $6.66B | $6.17B | $6.22B | $6.50B | $6.16B | $5.78B | $5.98B | $6.07B |
| Net debt | $13.82B | $14.09B | $13.89B | $13.74B | $13.14B | $13.45B | $12.59B | $12.28B |
| Shares outstanding | 164.80M | 164.60M | 166.90M | 169.60M | 170.30M | 170.00M | 174.10M | 176.10M |
| Cash flow statement | ||||||||
| Operating cash flow | $825.00M | $558.00M | $618.00M | $735.00M | $908.00M | $443.00M | $568.00M | $885.00M |
| Capital expenditure | $158.00M | $198.00M | $127.00M | $174.00M | $136.00M | $151.00M | $142.00M | $164.00M |
| Free cash flow | $667.00M | $360.00M | $491.00M | $561.00M | $772.00M | $292.00M | $426.00M | $721.00M |
| Investing cash flow | -$559.00M | -$381.00M | -$196.00M | -$1.10B | -$550.00M | -$346.00M | -$305.00M | -$310.00M |
| Financing cash flow | $78.00M | -$214.00M | -$433.00M | $535.00M | -$572.00M | $145.00M | -$258.00M | -$375.00M |
| Depreciation & amortization | $321.00M | $292.00M | $288.00M | $317.00M | $286.00M | $276.00M | $265.00M | $303.00M |
| Stock-based compensation | $83.00M | $95.00M | $65.00M | $60.00M | $55.00M | $60.00M | $72.00M | $48.00M |
| Share buybacks | $0 | $398.00M | $552.00M | $212.00M | $0 | $657.00M | $375.00M | $1.15B |
Free plan shows the latest 8 periods; Pro shows all 59 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.